<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="editorial"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Mark Access Health Policy</journal-id><journal-id journal-id-type="iso-abbrev">J Mark Access Health Policy</journal-id><journal-id journal-id-type="publisher-id">jmahp</journal-id><journal-title-group><journal-title>Journal of Market Access &#x00026; Health Policy</journal-title></journal-title-group><issn pub-type="epub">2001-6689</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12101405</article-id><article-id pub-id-type="doi">10.3390/jmahp13020022</article-id><article-id pub-id-type="publisher-id">jmahp-13-00022</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Joint Scientific Consultation Eligibility Criterion: Hubris or Na&#x000ef;vet&#x000e9;</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Toumi</surname><given-names>Mondher</given-names></name><xref rid="af1-jmahp-13-00022" ref-type="aff">1</xref><xref rid="c1-jmahp-13-00022" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Falissard</surname><given-names>Bruno</given-names></name><xref rid="af2-jmahp-13-00022" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1229-6622</contrib-id><name><surname>Boyer</surname><given-names>Laurent</given-names></name><xref rid="af1-jmahp-13-00022" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Auquier</surname><given-names>Pascal</given-names></name><xref rid="af1-jmahp-13-00022" ref-type="aff">1</xref></contrib></contrib-group><aff id="af1-jmahp-13-00022"><label>1</label>CEReSS/UR3279&#x02014;Health Services Research and Quality of Life Center, Aix-Marseille University, 13007 Marseille, France; <email>laurent.boyer@univ-amu.fr</email> (L.B.); <email>pascal.auquier@univ-amu.fr</email> (P.A.)</aff><aff id="af2-jmahp-13-00022"><label>2</label>CESP, INSERM U1018, Universit&#x000e9; Paris-Saclay, 91190 Villejuif, France; <email>bruno.falissard@gmail.com</email></aff><author-notes><corresp id="c1-jmahp-13-00022"><label>*</label>Correspondence: <email>mto@inovintell.com</email></corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>22</elocation-id><history><date date-type="received"><day>25</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>07</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Published by MDPI on behalf of the Market Access Society. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions></article-meta></front><body><p>The eligibility criteria for Joint Scientific Consultation (JSC) raise important questions about the approach taken by the Member State Coordination Group on Health Technology Assessment (HTACG). Two main requirements must be met for eligibility: first, the product must be subject to Joint Clinical Assessment (JCA), and second, the clinical investigations must still be in the planning phase. The guidance for selecting medicinal products for JSC, updated on 21 November 2024 [<xref rid="B1-jmahp-13-00022" ref-type="bibr">1</xref>], interprets the second criterion as &#x0201c;<italic toggle="yes">the pivotal study has not yet started and is still at a stage where the scientific recommendations of the HTACG could be taken into consideration in the final study protocol</italic> (i.e., <italic toggle="yes">the protocol has not been submitted to any regulatory authorities</italic>)&#x0201d;. Health Technology Developers (HTDs) must strictly comply with this requirement to qualify for JSC. However, it appears that this critical aspect may have been overlooked or dismissed as trivial, as there has been little or no discussion regarding its importance.</p><p>This situation raises concerns about either an inflated sense of confidence or a significant lack of awareness on the part of the newly formed HTACG&#x02014;an entity that is neither an official committee nor a fully operational body [<xref rid="B2-jmahp-13-00022" ref-type="bibr">2</xref>]. The HTACG has not yet begun any activities; its scope is extremely limited, its impact remains questioned and unproven, and its future will be rediscussed by the European Commission in 2028 [<xref rid="B3-jmahp-13-00022" ref-type="bibr">3</xref>]. It seems ambitious for such a group to attempt to supersede established authorities such as the European Medicines Agency (EMA) and the Food and Drug Administration (FDA), which have decades of experience in scientific consultation and initiated a parallel scientific advice process back in 2005 [<xref rid="B4-jmahp-13-00022" ref-type="bibr">4</xref>].</p><p>In terms of market context, the United States (U.S.) pharmaceutical market was valued at USD 602 billion in 2023 [<xref rid="B5-jmahp-13-00022" ref-type="bibr">5</xref>], translating to approximately USD 1800 per capita, while Europe&#x02019;s market stood at USD 285 billion with USD 462 per capita [<xref rid="B6-jmahp-13-00022" ref-type="bibr">6</xref>]. The U.S. accounts for 53.3% of the global pharmaceutical market compared to Europe&#x02019;s 22.7%. Furthermore, between 2018 and 2023, new medicine revenues were dominated by the U.S. at 67.1%, while Europe contributed only 15.8% [<xref rid="B7-jmahp-13-00022" ref-type="bibr">7</xref>]. Given these figures, it is unlikely that HTDs will prioritize JSC in the EU without first discussing their development plans with the FDA, and likely the EMA as well. Although parallel scientific advice is possible between EMA and the JSC subgroup [<xref rid="B8-jmahp-13-00022" ref-type="bibr">8</xref>], it remains to be seen how effectively this will function.</p><p>Despite being termed a Health Technology Assessment (HTA) regulation, the European HTA (EU-HTA) primarily addresses less critical elements of the HTA process. It reviews clinical evidence without contextual analysis and lacks critical evaluative judgment [<xref rid="B2-jmahp-13-00022" ref-type="bibr">2</xref>]. The most crucial steps&#x02014;contextualization and appraisal&#x02014;remain deliberative processes delegated to Member States (MSs) [<xref rid="B2-jmahp-13-00022" ref-type="bibr">2</xref>].</p><p>For instance, onasemnogene abeparvovec (ZOLGENSMA<sup>&#x000ae;</sup>) in France might not have qualified for reimbursement under a decontextualized analysis due to insufficient comparative data and small sample sizes; however, it received a Clinical Added Value (ASMR III) rating because of its significant therapeutic outcomes [<xref rid="B9-jmahp-13-00022" ref-type="bibr">9</xref>]. Similarly, while a decontextualized assessment might have excluded ZOLGENSMA<sup>&#x000ae;</sup>, the National Institute for Health and Care Excellence (NICE) endorsed it for Type I and II Spinal Muscular Atrophy (SMA) by incorporating contextual factors and patient perspectives [<xref rid="B10-jmahp-13-00022" ref-type="bibr">10</xref>]. Context is critical in reimbursement decisions.</p><p>Both the French National Health Authority (HAS) [<xref rid="B11-jmahp-13-00022" ref-type="bibr">11</xref>] and the German Federal Joint Committee (G-BA) [<xref rid="B12-jmahp-13-00022" ref-type="bibr">12</xref>] have indicated that additional analyses beyond the JCA report will be required for evaluating medicinal products submitted to their agencies. Therefore, the actual impact of JCA on national HTA and reimbursement decisions remains uncertain. In this context, it is surprising that the HTACG, yet to be established and survive, seeks to be the first to comment on clinical development plans. It would have been more appropriate to request that the final version of the protocol not be endorsed by any regulatory authority, thus leaving room for further adjustment eventually requested by the JSC group. It is likely that this mandatory eligibility condition for JSC will not be consistently enforced in practice and may require rapid revision for consistency.</p></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>M.T. conceptualized the content and wrote the first draft of the manuscript. The co-authors B.F., L.B. and P.A. challenged the concept, edited the manuscript, and refined arguments for clarity and coherence. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">ASMR</td><td align="left" valign="middle" rowspan="1" colspan="1">Clinical Added Value</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EMA</td><td align="left" valign="middle" rowspan="1" colspan="1">European Medicines Agency</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EU-HTA</td><td align="left" valign="middle" rowspan="1" colspan="1">European Health Technology Assessment</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FDA</td><td align="left" valign="middle" rowspan="1" colspan="1">Food and Drug Administration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">G-BA</td><td align="left" valign="middle" rowspan="1" colspan="1">German Federal Joint Committee</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HAS</td><td align="left" valign="middle" rowspan="1" colspan="1">French National Health Authority</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HTA</td><td align="left" valign="middle" rowspan="1" colspan="1">Health Technology Assessment</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HTACG</td><td align="left" valign="middle" rowspan="1" colspan="1">Member State Coordination Group on Health Technology Assessment</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HTDs</td><td align="left" valign="middle" rowspan="1" colspan="1">Health Technology Developers</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">JCA</td><td align="left" valign="middle" rowspan="1" colspan="1">Joint Clinical Assessment</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">JSC</td><td align="left" valign="middle" rowspan="1" colspan="1">Joint Scientific Consultation</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MSs</td><td align="left" valign="middle" rowspan="1" colspan="1">Member States</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NICE</td><td align="left" valign="middle" rowspan="1" colspan="1">National Institute for Health and Care Excellence</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SMA</td><td align="left" valign="middle" rowspan="1" colspan="1">Spinal Macular Atrophy</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">U.S.</td><td align="left" valign="middle" rowspan="1" colspan="1">United States</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-jmahp-13-00022"><label>1.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>HTA Coordination Group (HTACG)</collab>
</person-group><article-title>Guidance for the Selection of Medicinal Products (MP) for Joint Scientific Consultations (JSC), V3.2</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://health.ec.europa.eu/document/download/c4481261-8c18-43bf-aee9-16c065ede950_en?filename=hta_jsc_mp_selection-guidance_en.pdf" ext-link-type="uri">https://health.ec.europa.eu/document/download/c4481261-8c18-43bf-aee9-16c065ede950_en?filename=hta_jsc_mp_selection-guidance_en.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-16">(accessed on 16 December 2024)</date-in-citation></element-citation></ref><ref id="B2-jmahp-13-00022"><label>2.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>European Commission</collab>
</person-group><article-title>Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on Health Technology Assessment and Amending Directive 2011/24/EU</article-title><year>2021</year><comment>Available online: <ext-link xlink:href="https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32021R2282" ext-link-type="uri">https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32021R2282</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-18">(accessed on 18 December 2024)</date-in-citation></element-citation></ref><ref id="B3-jmahp-13-00022"><label>3.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>European Commission</collab>
</person-group><article-title>Member State Coordination Group on HTA (HTACG)</article-title><comment>Available online: <ext-link xlink:href="https://health.ec.europa.eu/health-technology-assessment/implementation-regulation-health-technology-assessment/member-state-coordination-group-hta-htacg_en" ext-link-type="uri">https://health.ec.europa.eu/health-technology-assessment/implementation-regulation-health-technology-assessment/member-state-coordination-group-hta-htacg_en</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-06">(accessed on 6 January 2025)</date-in-citation></element-citation></ref><ref id="B4-jmahp-13-00022"><label>4.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>The European Medicines Agency (EMA)</collab>
</person-group><article-title>EMA/FDA Parallel Scientific Advice (PSA)</article-title><year>2021</year><comment>Available online: <ext-link xlink:href="https://www.ema.europa.eu/en/documents/presentation/ema-fda-parallel-scientific-advice-psa_en.pdf" ext-link-type="uri">https://www.ema.europa.eu/en/documents/presentation/ema-fda-parallel-scientific-advice-psa_en.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-30">(accessed on 30 January 2025)</date-in-citation></element-citation></ref><ref id="B5-jmahp-13-00022"><label>5.</label><element-citation publication-type="webpage"><article-title>BioSpace. U.S. Pharmaceutical Market Size to Reach USD 1,093.79 Billion By 2033</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://www.biospace.com/u-s-pharmaceutical-market-size-to-reach-usd-1-093-79-billion-by-2033" ext-link-type="uri">https://www.biospace.com/u-s-pharmaceutical-market-size-to-reach-usd-1-093-79-billion-by-2033</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-10">(accessed on 10 January 2025)</date-in-citation></element-citation></ref><ref id="B6-jmahp-13-00022"><label>6.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Nova One Advisor</collab>
</person-group><article-title>Europe Pharmaceutical Market Size and Trends</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://www.novaoneadvisor.com/report/europe-pharmaceutical-market" ext-link-type="uri">https://www.novaoneadvisor.com/report/europe-pharmaceutical-market</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-10">(accessed on 10 January 2025)</date-in-citation></element-citation></ref><ref id="B7-jmahp-13-00022"><label>7.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>European Federation of Pharmaceutical Industries and Associations (EFPIA)</collab>
</person-group><article-title>The Pharmaceutical Industry in Figures&#x02014;Key Data</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://efpia.eu/media/2rxdkn43/the-pharmaceutical-industry-in-figures-2024.pdf?utm_source=chatgpt.com" ext-link-type="uri">https://efpia.eu/media/2rxdkn43/the-pharmaceutical-industry-in-figures-2024.pdf?utm_source=chatgpt.com</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-15">(accessed on 15 January 2025)</date-in-citation></element-citation></ref><ref id="B8-jmahp-13-00022"><label>8.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>HTA Coordination Group (HTACG)</collab>
</person-group><article-title>Procedural Guidance for Joint Scientific Consultations (JSC) on Medicinal Products (MP)</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://health.ec.europa.eu/publications/procedural-guidance-joint-scientific-consultations-jsc-medicinal-products-mp_en" ext-link-type="uri">https://health.ec.europa.eu/publications/procedural-guidance-joint-scientific-consultations-jsc-medicinal-products-mp_en</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-20">(accessed on 20 January 2025)</date-in-citation></element-citation></ref><ref id="B9-jmahp-13-00022"><label>9.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Haute Autorit&#x000e9; de Sant&#x000e9; (HAS)</collab>
</person-group><article-title>Commission de la Transparence Avis Onasemnogene Abeparvovec (ZOLGENSMA&#x000ae;)</article-title><year>2020</year><comment>Available online: <ext-link xlink:href="https://www.has-sante.fr/upload/docs/evamed/CT-18743_ZOLGENSMA_PIC_INS_AvisDef_CT18743.pdf" ext-link-type="uri">https://www.has-sante.fr/upload/docs/evamed/CT-18743_ZOLGENSMA_PIC_INS_AvisDef_CT18743.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-20">(accessed on 20 December 2024)</date-in-citation></element-citation></ref><ref id="B10-jmahp-13-00022"><label>10.</label><element-citation publication-type="webpage"><article-title>National Institute for Health and Care Excellence (NICE). Highly Specialised Technologies Guidance. Onasemnogene abeparvovec for Treating Spinal Muscular Atrophy</article-title><year>2021</year><comment>Available online: <ext-link xlink:href="https://www.nice.org.uk/guidance/hst15/resources/onasemnogene-abeparvovec-for-treating-spinal-muscular-atrophy-pdf-50216260528069" ext-link-type="uri">https://www.nice.org.uk/guidance/hst15/resources/onasemnogene-abeparvovec-for-treating-spinal-muscular-atrophy-pdf-50216260528069</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-18">(accessed on 18 December 2024)</date-in-citation></element-citation></ref><ref id="B11-jmahp-13-00022"><label>11.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>PharmaBoardroom</collab>
</person-group><article-title>Maintaining Independence Is Paramount Because We Must Never Be Beholden, in Any Way, to Either Industry Interests or Governmental Influence</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://pharmaboardroom.com/interviews/lionel-collet-president-haute-autorite-de-sante-has-france/" ext-link-type="uri">https://pharmaboardroom.com/interviews/lionel-collet-president-haute-autorite-de-sante-has-france/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-13">(accessed on 13 January 2025)</date-in-citation></element-citation></ref><ref id="B12-jmahp-13-00022"><label>12.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Dietrich</surname><given-names>E.S.</given-names></name>
</person-group><source>EU HTA Impact on Innovations: Expectations and Challenges of EU HTA for Germany&#x02014;HTA Perspective</source><publisher-name>ISPOR</publisher-name><publisher-loc>Copenhagen, Denmark</publisher-loc><year>2023</year><comment>Available online: <ext-link xlink:href="https://www.ispor.org/docs/default-source/euro2023/eu-hta-13-nov-2023-291023dietrich.pdf?sfvrsn=f59eb868_0" ext-link-type="uri">https://www.ispor.org/docs/default-source/euro2023/eu-hta-13-nov-2023-291023dietrich.pdf?sfvrsn=f59eb868_0</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-16">(accessed on 16 December 2024)</date-in-citation></element-citation></ref></ref-list></back></article>